查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1631141

胰島素市場規模、佔有率和趨勢分析報告：按產品類型、按應用、按分銷管道、按地區和細分市場預測，2025-2030

Insulin Market Size, Share & Trends Analysis Report By Product (Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin, Biosimilar), By Application, By Type, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

胰島素市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球胰島素市場規模預計將達到232.1億美元，預計2025年至2030年複合年成長率為3.7%。

該市場是寡占的，由諾和諾德公司、賽諾菲公司和禮來公司等公司主導。糖尿病盛行率的增加和胰島素輸送配方的進步是推動成長的主要因素。然而，生物相似藥和GLP-1 RA等2型糖尿病藥物的存在可能會在一定程度上減緩市場成長。

糖尿病是世界上成長最快的慢性疾病之一。在過去的幾十年裡，其盛行率穩定上升。在低收入和中等收入國家，盛行率正在迅速增加，其中四分之三的成年人患有糖尿病。根據國際糖尿病聯盟（IDF）2021年的資料，2030年約有6.43億人患有糖尿病，2045年將有7.83億人患有糖尿病。此外，老年人和肥胖人口的增加是推動成長的另一個因素。肥胖族群有罹患第 2 型糖尿病的風險。據世界衛生組織稱，2020 年有 19 億成年人超重，佔該年齡層的 39%。

胰島素輸送系統的配方進步正在開發中，它們的推出可能會在預測期內推動市場。 2019年12月，Tandem Diabetes Care的可互通設備Control-IQ在美國獲得FDA上市核准。這是一種自動胰島素劑量演算法，可與其他可互通設備一起使用。

它由三大製造公司主導：禮來公司、諾和諾德公司和賽諾菲。這些公司佔了90%以上的市場佔有率。由於市場寡占和專利保護，胰島素的成本很高。因此，產品高成本可能會阻礙產業的成長。

COVID-19 大流行對該行業產生了負面影響。患有糖尿病等慢性病的人在獲得緊急和常規醫療護理方面存在很大困難。根據 NCBI報導，在美國約 3,000 萬名糖尿病患者中，約有 750 萬人依賴胰島素。由於供應問題，胰島素發行和囤積已經是一個普遍的問題，在大流行期間有所增加。然而，在一些國家，COVID-19 的影響從 2020 年第三季開始減弱，支撐了市場復甦。

胰島素市場報告亮點

  • 長效胰島素製劑佔市場主導地位，2024年銷售佔有率最大，為52.4%。
  • 1 型糖尿病細分市場佔據主導地位，2024 年佔最大銷售佔有率，達 78.8%。
  • 模擬胰島素細分市場佔據主導地位，由於其優於人類胰島素的優勢，2024 年將佔最大收益佔有率，達到 87.3%。
  • 零售藥品領域佔市場主導地位，2024 年收益佔有率最大，達 90.0%。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章胰島素市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 胰島素市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第 4 章 胰島素市場：依產品分類的估計與趨勢分析

  • 細分儀表板
  • 胰島素市場：按產品分類的波動分析
  • 胰島素市場：按產品分類的前景
  • 市場規模、預測與趨勢分析（2018-2030）
  • 速效胰島素
  • 長效胰島素
  • 複合胰島素
  • 生物相似藥
  • 其他

第5章胰島素市場：按類型估計和趨勢分析

  • 細分儀表板
  • 胰島素市場：按類型波動分析
  • 胰島素市場：按類型分類的展望
  • 市場規模、預測與趨勢分析（2018-2030）
  • 人類胰島素
  • 胰島素類似物

第6章胰島素市場：按應用估計和趨勢分析

  • 細分儀表板
  • 胰島素市場：按應用分類的波動分析
  • 胰島素市場：依應用分類的前景
  • 市場規模、預測與趨勢分析（2018-2030）
  • 1型糖尿病
  • 2型糖尿病

第7章胰島素市場：按分銷管道的估計和趨勢分析

  • 細分儀表板
  • 胰島素市場：通路波動分析
  • 胰島素市場：按分銷管道分類的展望
  • 市場規模、預測與趨勢分析（2018-2030）
  • 醫院
  • 零售藥房
  • 其他

第8章胰島素市場：按地區估計和趨勢分析

  • 區域儀表板
  • 市場規模、預測與趨勢分析（2018-2030）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 市場參與企業分類
  • 主要市場參與企業的最新趨勢和影響分析
  • 2024 年企業市場佔有率分析
  • 主要企業簡介
    • Novo Nordisk A/S
    • Eli Lilly and Company
    • Sanofi
    • Biocon Ltd
    • Wockhardt
    • Boehringer Ingelheim International GmbH
    • Julphar
    • United Laboratories International Holdings Limited
    • Tonghua Dongbao Pharmaceutical Co. Ltd.
Product Code: GVR-4-68039-951-3

Insulin Market Growth & Trends:

The global insulin market size is estimated to reach USD 23.21 billion by 2030, registering to grow at a CAGR of 3.7% from 2025 to 2030 according to a new report by Grand View Research, Inc. It is an oligopolistic space dominated by companies such as Novo Nordisk A/S, Sanofi, and Eli Lilly and Company. The increasing incidence of diabetes and formulation advancements in insulin delivery are the primary factors driving growth. However, the presence of biosimilars and drugs such as GLP-1 RAs for the treatment of type 2 diabetes can slow down market growth to a certain extent.

Diabetes is one of the fastest-growing chronic diseases in the world. Its prevalence has increased steadily over the past few decades. The prevalence of the disease is growing rapidly in low- and middle-income countries; three in four adults live with diabetes in these countries. According to the International Diabetes Federation (IDF) data from 2021, approximately 643 million individuals will have diabetes by 2030 and 783 million by 2045. In addition, the increase in geriatric and obese populations is another factor driving growth. The overweight population is at risk of developing type 2 diabetes mellitus. According to WHO, in 2020, 1.9 billion adults were found to be overweight, accounting for 39% of the population within that age group.

Formulation advancements in insulin delivery systems are being developed, the release of which is likely to propel the market over the forecast period. In December 2019, Tandem Diabetes Care's Control-IQ, an interoperable device, received FDA authorization for marketing in the U.S. It is an automated insulin dosing algorithm that can be used with other interoperable devices.

The top three manufacturing companies, Eli Lilly and Company, Novo Nordisk A/S, and Sanofi, hold a monopoly. These companies hold more than 90% of the market share. Owing to the oligopolistic nature of the market and patent protection, the cost of insulin is high. Hence, the high cost of products could impede industry growth.

The COVID-19 pandemic caused a detrimental impact on the industry. Individuals with chronic illnesses, such as diabetes, have experienced substantial disruptions in emergency and routine medical care. According to an NCBI article, out of ~30 million diabetic patients in America, about 7.5 million are dependent on insulin. Insulin rationing or hoarding has already been a rampant issue, which increased further amid the pandemic due to supply concerns. However, in several countries, the effect of COVID-19 declined to post the third quarter of 2020, which helped the market regain traction.

Insulin Market Report Highlights:

  • The long-acting insulin segment dominated the market and accounted for the largest revenue share of 52.4% in 2024.
  • The type 1 diabetes mellitus segment dominated the market and accounted for the largest revenue share of 78.8% in 2024, driven by the rising incidence of this autoimmune condition among children and adults.
  • The analog insulin segment dominated the market and accounted for the largest revenue share of 87.3% in 2024 due to its advantages over human insulin.
  • The retail pharmacy segment dominated the market and accounted for the largest revenue share of 90.0% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Type
    • 1.2.3. Application
    • 1.2.4. Distribution Channel
    • 1.2.5. Regional Scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Insulin Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increase in prevalence of diabetes
      • 3.2.1.2. Increase in geriatric and obese population
      • 3.2.1.3. Formulation advancements in insulin delivery systems
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of insulin
      • 3.2.2.2. Poor reimbursement policies
      • 3.2.2.3. Launch of insulin biosimilars and increasing penetration of glp-1 agonists
  • 3.3. Insulin Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Insulin Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Insulin Market: Product Movement Analysis
  • 4.3. Insulin Market by Product Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Rapid-Acting Insulin
    • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Long-Acting Insulin
    • 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Combination Insulin
    • 4.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Biosimilar
    • 4.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Insulin Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Insulin Market: Type Movement Analysis
  • 5.3. Insulin Market by Type Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Human Insulin
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Insulin Analog
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Insulin Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Insulin Market: Application Movement Analysis
  • 6.3. Insulin Market by Application Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Type 1 Diabetes Mellitus
    • 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Type 2 Diabetes Mellitus
    • 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Insulin Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Insulin Market: Distribution Channel Movement Analysis
  • 7.3. Insulin Market by Distribution Channel Outlook (USD Million)
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.5. Hospitals
    • 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Retail Pharmacies
    • 7.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Others
    • 7.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Insulin Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Dashboard
  • 8.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Recent Developments & Impact Analysis by Key Market Participants
  • 9.3. Company Market Share Analysis, 2024
  • 9.4. Key Company Profiles
    • 9.4.1. Novo Nordisk A/S
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Eli Lilly and Company
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Sanofi
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Biocon Ltd
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Wockhardt
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Boehringer Ingelheim International GmbH
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Julphar
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. United Laboratories International Holdings Limited
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Tonghua Dongbao Pharmaceutical Co. Ltd.
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. List of secondary sources
  • Table 4. List of Abbreviations
  • Table 5. North America insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 6. North America insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 7. North America insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 8. North America insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9. U.S. insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 10. U.S. insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 11. U.S. insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 12. U.S. insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13. Canada insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 14. Canada insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 15. Canada insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 16. Canada insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17. Europe insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 18. Europe insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 19. Europe insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 20. Europe insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 21. UK insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 22. UK insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 23. UK insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 24. UK insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25. Germany insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 26. Germany insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 27. Germany insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 28. Germany insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29. France insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 30. France insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 31. France insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 32. France insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33. Italy insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 34. Italy insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 35. Italy insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 36. Italy insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37. Spain insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 38. Spain insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 39. Spain insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 40. Spain insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41. Asia Pacific insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 42. Asia Pacific insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 43. Asia Pacific insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 44. Asia Pacific insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45. Japan insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 46. Japan insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 47. Japan insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 48. Japan insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49. China insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 50. China insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 51. China insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 52. China insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53. India insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 54. India insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 55. India insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 56. India insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57. Australia insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 58. Australia insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 59. Australia insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 60. Australia insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61. South Korea insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 62. South Korea insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 63. South Korea insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 64. South Korea insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65. Latin America insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 66. Latin America insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 67. Latin America insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 68. Latin America insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69. Brazil insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 70. Brazil insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 71. Brazil insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 72. Brazil insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 73. Mexico insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 74. Mexico insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 75. Mexico insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 76. Mexico insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77. Argentina insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 78. Argentina insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 79. Argentina insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 80. Argentina insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 81. MEA insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 82. MEA insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 83. MEA insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 84. MEA insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 85. South Africa insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 86. South Africa insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 87. South Africa insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 88. South Africa insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 89. Saudi Arabia insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 90. Saudi Arabia insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 91. Saudi Arabia insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 92. Saudi Arabia insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93. UAE insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 94. UAE insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 95. UAE insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
  • Table 96. UAE insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD) Million
  • Table 97. List of key distributors

List of Figures

  • Fig. 1 Market research approaches
  • Fig. 2 Value chain-based sizing & forecasting
  • Fig. 3 Market formulation & validation
  • Fig. 4 Insulin market segmentation
  • Fig. 5 Market driver analysis (current & future impact)
  • Fig. 6 Market restraint analysis (current & future impact)
  • Fig. 7 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 8 Porter's five forces analysis
  • Fig. 9 Global insulin market: Product type outlook and key takeaways
  • Fig. 10 Global insulin market: Product type movement analysis
  • Fig. 11 Rapid-acting insulin market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 12 Long-acting insulin market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 13 Combination Insulin market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 14 Biosimilar market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 Others market estimates and forecast, estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Global insulin market: type outlook and key takeaways
  • Fig. 17 Global insulin market: Type movement analysis
  • Fig. 18 Human insulin market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 19 Insulin Analog market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 20 Global Insulin market: Application type outlook and key takeaways
  • Fig. 21 Global insulin market: Application type movement analysis
  • Fig. 22 Type 1 diabetes mellitus market estimates and forecast, 2018-2030
  • Fig. 23 Type 2 diabetes mellitus market estimates and forecast, 2018-2030
  • Fig. 24 Global insulin market: Distribution channel outlook and key takeaways
  • Fig. 25 Global insulin market: Distribution channel movement analysis
  • Fig. 26 Hospital pharmacy market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 27 Retail pharmacy market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 North America Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 US Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Canada Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Europe Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 UK Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Germany Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 France Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Italy Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Spain Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Norway Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Asia Pacific Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Japan Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 China Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 India Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Australia Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Thailand Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 South Korea Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Brazil Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Argentina Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 MEA Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 UAE Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Kuwait Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 List of key emerging company's/disruptors/innovators